ATTACHMENT J: ACTEMRA REMS WEBSITE SCREENSHOT
Risk Evaluation and Mitigation Strategy (REMS)

A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration to ensure that the benefits outweigh its risks.

To learn more about serious risks, read the Important Safety Information and Medication Guide and discuss it with your patients.

The goal of the ACTEMRA REMS is:

- To inform healthcare providers about the serious risks associated with ACTEMRA.

Genentech recommends laboratory monitoring of patients being treated with ACTEMRA due to the potential consequences of treatment-related abnormalities in liver function, lipids, neutrophils and platelets. If you become aware of a patient who has developed a serious adverse event while being treated with ACTEMRA, it is important that you report the case, even if you do not think there is a causal relationship. The information you provide about these events may inform therapy and monitoring decisions.

Continue to check back on this Web site. It will be updated to include additional information intended to assist in the proper communication of the risks and benefits of ACTEMRA.

Prescriber Education Slide Deck

Healthcare Professional Letters

Journal Information Pieces

For more information on safety, please click here.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SARAH K YIM
10/21/2013
Signing for Badrul Chowdhury, M.D., Ph.D.